Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Conditions are getting a bit more challenging for the drugmaker.

Healthcare giant Eli Lilly (NYSE: LLY) has been trading at an inflated valuation for some time thanks to excitement around ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

It's shaping up to be a tough period for Eli Lilly and Company , which a week ago released some disappointing third-quarter ...

We recently compiled a list of the 10 Best S&P 500 Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Eli Lilly (LLY) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. During an earnings call Wednesday, Eli Lilly instead blamed ...